Study on the Effects of Azeliragon for Patients with Metastatic Pancreatic Cancer Not Responding to Previous Treatments

Inclusion Criteria

• Have a confirmed diagnosis of advanced or metastatic pancreatic cancer that cannot be treated with surgery.
• Previously treated with chemotherapy regimens like Gemcitabine/Abraxane or FOLFIRINOX.
• Any side effects from previous chemotherapy, except hair loss, should have improved to a mild level or returned to baseline.
• Be a male or a non-pregnant, non-breastfeeding female aged between 18 and 80.
• Have adequate blood counts and organ function as shown by specific blood tests.
• Have a performance status score of 2 or less, indicating the ability to carry out daily activities with some limitations.
• Understand the study details and agree to participate by signing an informed consent form.

Exclusion Criteria

• Have a life expectancy of less than 3 months.
• Have a performance status score that worsens to more than 2 before starting the study drug.
• Have active, uncontrolled infections requiring treatment.
• Are taking certain medications that interfere with the study drug.
• Have serious medical or psychiatric conditions that could affect safety or study results.
• Are unable or unwilling to follow study procedures, including taking oral medication.
• Have digestive issues that affect swallowing or absorbing medication.
• Are sexually active and not using effective birth control methods if of childbearing potential.
• Are participating in another interventional clinical trial or have used another investigational drug within 14 days before starting the study drug. Participation in non-interventional studies is allowed.